Novo Nordisk (NYSE:NVO) shares closed at US$48.18, with recent returns mixed, including a decline over the past week and gains over the past month and past 3 months. Investors may focus on how the current valuation reflects these moves.

Looking beyond the recent weekly pullback, Novo Nordisk’s 90 day share price return of 17.03% contrasts with a year to date share price return that is down 8.04%, while the 1 year total shareholder return is down 29.64%, suggesting momentum has cooled after a stronger stretch.

If you are weighing Novo Nordisk against other opportunities in healthcare, this is a good moment to see what the market is pricing into 41 healthcare AI stocks

Novo Nordisk’s scale in diabetes and obesity care is clear, but the recent share price pullback after a strong 90 day run raises a sharper question: is this still a quality business at a sensible price today?

Most Popular Narrative: 53.2% Undervalued

The latest narrative on Novo Nordisk compares a fair value of $102.97 to a last close of $48.18, framing the recent pullback against a much higher implied value.

The GLP-1 market is growing at an unprecedented rate, with global sales projected to more than double from 2025 levels to reach $190 billion to $200 billion by 2035, with some forecasts projecting the market to exceed $250 billion by 2030-2034 due to the expansion into new therapeutic areas and rapid adoption of oral treatments.

According to MCOInvestors, this fair value hinges on a blend of moderated revenue growth, higher margins, and a future earnings multiple that differs from today. Want to see how those ingredients fit together, and how oral GLP-1 expectations are built into the numbers, without being fully spelled out in the headline figure.

Result: Fair Value of $102.97 (UNDERVALUED)

However, this Novo Nordisk narrative can be challenged if oral GLP-1 adoption or adolescent approvals are slower than hoped, or if proposed FDA compounding limits change.

Next Steps

With mixed sentiment around Novo Nordisk, this is the kind of setup where acting early on your own view matters. Weigh both sides carefully and review the 3 key rewards and 4 important warning signs.

Looking for more investment ideas beyond Novo Nordisk?

If you want a stronger handle on where to put your next dollar, let the Simply Wall Street Screener surface fresh ideas before the crowd catches on.

• Target steadier compounders by reviewing companies flagged in the 82 resilient stocks with low risk scores that aim to balance growth potential with lower overall risk scores.
• Hunt for value by checking companies highlighted in the 47 high quality undervalued stocks that combine quality fundamentals with prices that differ from underlying metrics.
• Spot potential future standouts by scanning the screener containing 20 high quality undiscovered gems where strong financials have not yet attracted broad investor attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.